Quantitative Systematic Strategies LLC Vertex Pharmaceuticals Inc Transaction History

Quantitative Systematic Strategies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	SELL	$181.39 - $202.99 $319,609 - $357,668	-1,762 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$187.49 - $221.1 $691,838 - $815,859	-3,690 Reduced 67.68%	1,762 $355,000
Q1 2021 May 06, 2021	BUY	$207.02 - $241.31 $224,616 - $261,821	1,085 Added 24.85%	5,452 $1.17 Million
Q4 2020 Feb 09, 2021	BUY	$207.01 - $276.09 $904,012 - $1.21 Million	4,367 New	4,367 $1.03 Million
Q1 2019 Apr 15, 2019	SELL	$163.73 - $194.7 $259,839 - $308,988	-1,587 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$151.91 - $192.21 $241,081 - $305,037	1,587 New	1,587 $263,000
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $259,646 - $298,361	-1,548 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$145.72 - $169.96 $225,574 - $263,098	1,548 New	1,548 $263,000
Q4 2017 Feb 01, 2018	SELL	$137.28 - $155.55 $340,454 - $385,764	-2,480 Closed	0 $0
Q3 2017 Oct 18, 2017	BUY	$148.13 - $162.24 $367,362 - $402,355	2,480	2,480 $377,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.